β-Glucan-modified nanoparticles with different particle sizes exhibit different lymphatic targeting efficiencies and adjuvant effects
10.1016/j.jpha.2024.02.007
- Author:
Wen GUO
1
;
Xinyue ZHANG
;
Long WAN
;
Zhiqi WANG
;
Meiqi HAN
;
Ziwei YAN
;
Jia LI
;
Ruizhu DENG
;
Shenglong LI
;
Yuling MAO
;
Siling WANG
Author Information
1. Department of Pharmaceutics,School of Pharmacy,Shenyang Pharmaceutical University,Shenyang,110016,China
- Publication Type:Journal Article
- Keywords:
Smart nanoparticles;
Immunomodulatory nano-vaccine;
Lymph node targeting;
Mesoporous silica nanoparticles;
Dendritic cells mature
- From:
Journal of Pharmaceutical Analysis
2024;14(12):1868-1878
- CountryChina
- Language:English
-
Abstract:
Particle size and surface properties are crucial for lymphatic drainage(LN),dendritic cell(DC)uptake,DC maturation,and antigen cross-presentation induced by nanovaccine injection,which lead to an effective cell-mediated immune response.However,the manner in which the particle size and surface properties of vaccine carriers such as mesoporous silica nanoparticles(MSNs)affect this immune response is un-known.We prepared 50,100,and 200 nm of MSNs that adsorbed ovalbumin antigen(OVA)while modifying β-glucan to enhance immunogenicity.The results revealed that these MSNs with different particle sizes were just as efficient in vitro,and MSNs with β-glucan modification demonstrated higher efficacy.However,the in vivo results indicated that MSNs with smaller particle sizes have stronger lymphatic targeting efficiency and a greater ability to promote the maturation of DCs.The results also indicate that β-glucan-modified MSN,with a particle size of-100 nm,has a great potential as a vaccine delivery vehicle and immune adjuvant and offers a novel approach for the delivery of multiple thera-peutic agents that target other lymph-mediated diseases.
